![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1.jpg?resize=440%2C310&ssl=1 "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] – EMBL-EBI")
Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] – EMBL-EBI
✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologySafetyMental HealthCBDTHCAnxiety Why This Matters This research characterizing MAGL (monoacylglycerol…
Study Found Teen Cannabis Use Interferes with the Brain’s Reward System
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyTHCMental HealthPediatricsSafetyAnxiety Why This Matters Clinicians should understand that adolescent…
CBD for Skin Care: Evidence-Based Benefits & Research
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDResearchAgingSafetyHempAnxietyMental Health Why This Matters Clinicians need to understand CBD’s mechanism in…
Using cannabis for sleep isn’t harmless – it can trap people in a cycle of dependency
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. SleepTHCSafetyMental HealthResearchDosingAnxiety Why This Matters Clinicians should understand that cannabis does not…
It may be legal for adults, but cannabis use a danger to young brains
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchPediatricsMental HealthSafetyNeurologyTHC Why This Matters Clinicians need to understand that legal adult…
Exilby Whole Plant Botanical Cannabis Treatment, Receives Marketing Authorization in Germany
✦ New CED Clinical Relevance#67 Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. ResearchPolicyIndustrySafetyDosingTHCCBD Why This MattersThis approval establishes a regulated, standardized cannabis product with…
Avextra 10/10 Cannabis Extract in Sesame Linseed Oil Shows Promise
A Phase II randomized controlled trial evaluated Avextra 10/10 cannabis extract clinical trial for treating neurodegenerative diseases using a rigorous double-blind design. The study assessed both therapeutic benefits and safety profiles of this…
Medical Cannabis for Autoimmune Pain Management According to Dr. Caplan
Patients with autoimmune conditions are increasingly turning to medical cannabis for autoimmune pain when traditional therapies prove insufficient. Dr. Caplan's clinical experience shows cannabis can provide meaningful adjunctive relief, though evidence…
Limited Evidence for Topical CBD Pain Relief According to Recent Study
Recent research challenges widespread claims about topical CBD for pain relief, finding insufficient evidence to support its effectiveness for musculoskeletal soreness. While topical CBD for pain has gained popularity among consumers, clinical trials…
The United States just offically recliassified cannabis. The federal reclassification of medical …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustrySafetyMental HealthPainAnxiety Why This Matters The reclassification of cannabis from Schedule I to…